株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のポンペ病治療市場:2025年までの予測

Global Pompe Disease Treatment Market Research Report Forecast to 2025

発行 Market Research Future 商品コード 916689
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
世界のポンペ病治療市場:2025年までの予測 Global Pompe Disease Treatment Market Research Report Forecast to 2025
出版日: 2019年10月31日 ページ情報: 英文 78 Pages
概要

世界のポンペ病治療市場は、2025年までの間に2.6%のCAGRで成長する見通しで、2025年には14億1,410万米ドルに達すると予測されています。同市場を牽引する主な要因には、政府の取り組みの増加や、メーカーによる研究開発の増加が挙げられます。

当レポートは世界のポンペ病治療市場について調査しており、市場機会、成長および阻害要因、タイプ・療法・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

  • イントロダクション

第2章 市場の紹介

  • 調査範囲
  • 調査目的
  • 前提条件のリスト

第3章 調査方法

  • 調査方法
  • 一次調査
  • 二次調査
  • 市場規模の推定

第4章 市場力学

  • イントロダクション
  • 成長要因
    • 政府の取り組みの増加
    • メーカーによる研究開発活動の増加
  • 阻害要因
    • 高い治療費
  • 市場機会
    • 免疫療法的アプローチの出現
  • 課題

第5章 市場要因分析

  • バリューチェーン分析
    • 研究開発・設計
    • 製造業
    • 流通・販売
    • 販売後のサービス
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • バイヤーの交渉力
    • 新規参入の脅威
    • 代替品の脅威
    • 業界内の競争

第6章 市場分析:タイプ別

  • イントロダクション
  • 遅発性ポンペ病
  • 古典型乳児発症ポンペ病
  • 非古典型乳児発症ポンペ病

第7章 市場分析:療法別

  • イントロダクション
  • 酵素補充療法(ERT)
  • 遺伝子治療

第8章 市場分析:エンドユーザー別

  • イントロダクション
  • 病院・診療所
  • 研究機関・学術機関

第9章 市場分析:地域別

  • イントロダクション
  • 南北アメリカ
    • 北米
    • 南米
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • 中東・アフリカ
    • 中東
    • アフリカ

第10章 競合情勢

  • イントロダクション
  • 主な開発

第11章 企業プロファイル

  • Amicus Therapeutics, Inc
  • Genzyme Corporation
  • Audentes Therapeutics
  • Oxyrane
  • Valerion Therapeutics
  • AVROBIO, Inc.
  • CENTOGENE AG

第12章 付録

  • 参照資料
  • 関連レポート
図表

List of Tables

  • TABLE 1 LIST OF ASSUMPTIONS
  • TABLE 2 PRIMARY INTERVIEWS
  • TABLE 3 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 4 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR LATE-ONSET POMPE DISEASE, BY REGION 2016-2025 (USD MILLION)
  • TABLE 5 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016-2025 (USD MILLION)
  • TABLE 6 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR NON-CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016-2025 (USD MILLION)
  • TABLE 7 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR ENZYME REPLACEMENT THERAPY (ERT), BY REGION 2016-2025 (USD MILLION)
  • TABLE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR GENE THERAPY, BY REGION 2016-2025 (USD MILLION)
  • TABLE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 11 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION 2016-2025 (USD MILLION)
  • TABLE 12 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION 2016-2025 (USD MILLION)
  • TABLE 13 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION 2016-2025 (USD MILLION)
  • TABLE 14 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY REGION 2016-2025 (USD MILLION)
  • TABLE 15 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 16 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 17 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 18 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016-2025 (USD MILLION)
  • TABLE 19 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 20 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 21 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 22 US: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 23 US: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 24 US: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 25 CANADA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 26 CANADA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 27 CANADA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 28 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 29 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 30 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 31 EUROPE: POMPE DISEASE TREATMENT MARKET, BY COUNTRY/REGION 2016-2025 (USD MILLION)
  • TABLE 32 EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 33 EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 34 EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 35 GERMANY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 36 GERMANY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 37 GERMANY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 38 FRANCE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 39 FRANCE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 40 FRANCE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 41 UK: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 42 UK: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 43 UK: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 44 ITALY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 45 ITALY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 46 ITALY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 47 SPAIN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 48 SPAIN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 49 SPAIN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 50 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 51 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 52 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 53 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY COUNTRY/REGION 2016-2025 (USD MILLION)
  • TABLE 54 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 55 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 56 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 57 CHINA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 58 CHINA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 59 CHINA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 60 JAPAN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 61 JAPAN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 62 JAPAN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 63 INDIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 64 INDIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 65 INDIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 66 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 67 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 68 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 69 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 70 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 71 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 72 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 73 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 74 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 75 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY REGION 2016-2025 (USD MILLION)
  • TABLE 76 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 77 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 78 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 79 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 80 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 81 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 82 AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 83 AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016-2025 (USD MILLION)
  • TABLE 84 AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016-2025 (USD MILLION)
  • TABLE 85 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET
  • TABLE 86 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL POMPE DISEASE TREATMENT MARKET: STRUCTURE
  • FIGURE 3 RESEARCH PROCESS
  • FIGURE 4 TOP-DOWN AND BOTTOM-UP APPROACHES
  • FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL POMPE DISEASE TREATMENT MARKET
  • FIGURE 6 VALUE CHAIN: GLOBAL POMPE DISEASE TREATMENT MARKET
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL POMPE DISEASE TREATMENT MARKET
  • FIGURE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2018 & 2025 (USD MILLION)
  • FIGURE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2018 & 2025 (USD MILLION)
  • FIGURE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2018 & 2025 (USD MILLION)
  • FIGURE 11 GLOBAL POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)
  • FIGURE 12 AMERICAS: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)
  • FIGURE 13 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY 2018 (%)
  • FIGURE 14 EUROPE: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY/REGION 2018 (%)
  • FIGURE 15 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET SHARE, BYCOUNTRY/ REGION 2018 (%)
  • FIGURE 16 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)
目次

Pompe Disease Treatment Market Research Report - Global Forecast till 2025

Global Pompe Disease Treatment Market: Information by Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic Infantile-Onset Pompe Disease), by Therapy (Enzyme Replacement Therapy (ERT) and Gene Therapy), End User (Hospitals & Clinics and Research & Academic Institutes) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis

Pompe disease is a genetic metabolic disorder that is usually seen in infants. This disease is caused due to the mutations in the GAA gene which produces the acid, alpha-glucosidase enzyme, that translates glycogen into a simple form. The absence or mutation in the GAA gene results in the accumulation of glycogen that creates heart problems, muscle weakness, and liver harm that can lead to early death in newborns. Factors such as limited awareness about treatment methods and the high cost of therapy hinder market growth. The key factors that drive the Pompe disease treatment market are increasing government initiatives and increasing R&D by manufacturers. The Global Pompe Disease Treatment Market is likely to register a CAGR of 2.6% to attain USD 1,414.1 Million by the year 2025. The Orphan Products Grants funded 18 new grants from a total of 92 grant applications in 2015, to support around 67 ongoing clinical studies that are related to rare diseases as the government has been taking continuous initiatives for the progress and manufacture of advanced products for the diagnosis and treatment of rare diseases such as Pompe disease. Additionally, the governments of various countries such as Sweden, India, the Netherlands, and South Korea are focusing on approving guidelines for the reimbursement of patients enduring enzyme replacement therapy (ERT) for the treatment of Pompe disease. The State Government of Karnataka along with the Employee State Insurance Corporation provides free of cost ERT to patients with lysosomal storage disorders. Additionally, the Union Ministry of Health and Family Welfare has been taking active initiatives for producing a fund of an amount of 13,940 USD million for the treatment of rare diseases, including lysosomal storage disorders. These growing government initiatives for promoting and advancing Pompe disease treatment solutions are widely expected to spur growth of the global Pompe disease treatment market.

Market Segmentation

Global Pompe Disease Treatment Market has been segmented on the different basis. Based on Type the market has been segmented into Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease and Non-Classic Infantile-Onset Pompe Disease. Based on Therapy, the Global Pompe Disease Treatment Market has been segmented into Enzyme Replacement Therapy (ERT) and Gene Therapy. Based on End User the market has been segmented into hospitals & Clinics and Research & Academic Institutes. Based on region the market has been segmented into different regions like Americas covering North America ( US and Canada) and South America, Europe covering Germany, UK, France, Spain, Italy and Rest of Europe, Asia-Pacific covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific, Middle East & Africa. The acid alpha-glucosidase is responsible for breaking glycogen, a complex form of sugar, into its simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and damages the cells and Pompe disease is a infrequent genetic condition, caused due to the mutation in the GAA gene, which is responsible for making an enzyme called acid alpha-glucosidase. tissues. There are three chief segmentation of Pompe disease, each differing based on age and severity. These different segments are late-onset Pompe disease, non-classic infantile-onset Pompe disease, and classic infantile-onset Pompe disease. The treatment of Pompe disease is disease-specific and depends on the symptoms of the disease. The global Pompe disease treatment market on the basis of therapy has been divided into, enzyme replacement therapy (ERT), gene therapy, and others. The enzyme replacement therapy (ERT) segment captures the maximum share of the total market as it is the only Food and Drug Administration (FDA) approved therapy for the treatment of Pompe diseases. The Pompe disease treatment market has been fragmented, on the basis of end user, into hospitals & clinics and research & academic institutes. The hospitals & clinics segment was valued at USD 860.8 million in the year 2018, and the research & academic institutes segment accounted for a value of USD 320.7 million in 2018 and are expected to exhibit a CAGR of 2.3% during the forecast period.

Regional Analysis

Geographically, the global Pompe disease treatment market, based on region, has been split into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is responsible for the major share in the global Pompe disease treatment market owing to the grow in the number of patients with Pompe disease. As per the National Organization for Rare Disorders, the anticipated frequency of the occurrence Pompe disease is approximately 1 in 40,000 in the US. European Pompe disease treatment market is second largest market followed by Asia-Pacific. Europe responsible for the second-major market share in the Pompe disease treatment market owing to factors such as the growing research and development initiatives, support by government for the healthcare sector, and development in settlement policies have improved the market growth. Asia-Pacific is expected to be the fastest-growing region in the global Pompe disease treatment market during the forecast period. increasing healthcare expenditures, growing awareness among patients regarding rare disorders, and improved healthcare are factors which is affecting the the growth of the market. Due to low per capita income and absence of suitable healthcare infrastructure support, the Middle East & Africa responsible for a comparatively lesser market share in the year 2018

Major Players

The proposed spectators in global Pompe disease treatment market are hospitals, medical devices companies, Research and academic institutes, software companies Governments, associations, industrial bodies, etc. The major companies functioning in the global Pompe disease treatment market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers of the global Pompe disease treatment market are Market research and consulting service providers, Medical research laboratories and Academic medical institutes and universities, Drug Suppliers, Research and development (R&D) companies, Government research laboratories, Independent research laboratories, Government and independent regulatory authorities. Oxyrane, Valerion Therapeutics, AVROBIO, Inc., and CENTOGENE AG., Amicus Therapeutics, Inc., Genzyme Corporation, Audentes Therapeutics are some of major players in the global Pompe disease treatment market. The players operating in the global Pompe disease treatment market is focusing on product launches, along with expanding their global footprints by entering untapped markets.

Table of Contents

1 Executive Summary

  • 1.1 Introduction

2 Market Introduction

  • 2.1 Scope of the Study
  • 2.2 Research Objective
  • 2.3 List of Assumptions

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Increasing Government Initiatives
    • 4.2.2 Rising R&D Activities by Manufacturers
  • 4.3 Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Opportunities
    • 4.4.1 Emergence of Immunotherapeutic Approaches
  • 4.5 Challenges

5 Market Factor Analysis

  • 5.1 Value Chain Analysis
    • 5.1.1 R&D and Designing
    • 5.1.2 Manufacturing
    • 5.1.3 Distribution & Sales
    • 5.1.4 Post-Sales Services
  • 5.2 Porter's Five Forces Model
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Buyers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitutes
    • 5.2.5 Intensity of Rivalry

6 Global Pompe Disease Treatment Market, by Type

  • 6.1 Introduction
  • 6.2 Late-Onset Pompe Disease
  • 6.3 Classic Infantile-Onset Pompe Disease
  • 6.4 Non-Classic Infantile-Onset Pompe Disease

7 Global Pompe Disease Treatment Market, by Therapy

  • 7.1 Introduction
  • 7.2 Enzyme Replacement Therapy (ERT)
  • 7.3 Gene Therapy

8 Global Pompe Disease Treatment Market, by End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Research & Academic Institutes

9 Global Pompe Disease Treatment Market, by Region

  • 9.1 Introduction
  • 9.2 Americas
    • 9.2.1 North America
      • 9.2.1.1 US
      • 9.2.1.2 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 France
    • 9.3.3 UK
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia-Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 South Korea
    • 9.4.5 Australia
    • 9.4.6 Rest of Asia-Pacific
  • 9.5 Middle East & Africa
    • 9.5.1 Middle East
    • 9.5.2 Africa

10 Competitive Landscape

  • 10.1 Introduction
  • 10.2 Key developments

11 Company Profiles

  • 11.1 Amicus Therapeutics, Inc
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategies
  • 11.2 Genzyme Corporation
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategies
  • 11.3 Audentes Therapeutics
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offered
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategies
  • 11.4 Oxyrane
    • 11.4.1 Company Overview
    • 11.4.2 Financial Overview
    • 11.4.3 Products/Services Offered
    • 11.4.4 Key Developments
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Strategies
  • 11.5 Valerion Therapeutics
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered (Clinical Study)
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategies
  • 11.6 AVROBIO, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Financial Overview
    • 11.6.3 Products/Services Offered
    • 11.6.4 Key Developments
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Strategies
  • 11.7 CENTOGENE AG
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategies

12 Appendix

  • 12.1 References
  • 12.2 Related Reports
Back to Top